Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Poloxamer 188 oral solution versus PEG 3350 for infant dyschezia
IRCT20090808002306N11Phase 3Completed
- Sponsor
- Isfahan University of Medical Sciences
- Start
- Mar 2026
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, open-label trial of poloxamer 188 and polyethylene glycol 3350 in Infant dyschezia (2 arms), sponsored by Isfahan University of Medical Sciences. Primary endpoints: Defecation frequency and Defecation difficulty. Started Mar 2026; status: completed.
02
Drugs
poloxamer 188polyethylene glycol 3350
03
Conditions
Infant dyschezia
Beyond the preview
Go deeper on IRCT20090808002306N11.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20090808002306N11.